Juan Yermo, General Manager of Farmaindustria.
the Pharmaceutical innovation It focuses on the complementary amendment and development of approved drugs. This opens the possibility of expanding the number of medicines within a treatment category, an increase in the number of biology and management forms and improving Current drug propertiesIn addition to discovering synergy and eradication of the known active ingredients, among other advantages. However, “No” to the Public Health Agency It was also promoted to this innovation.
from Pharmaceutical The Spanish has long claimed more integration and it seems that with the arrival State Public Health Agency Law It will be closer to achieving it because it guarantees a modification of transactions as there was a proposal Amending Article 98 of the Guarantee Law And rational use of medicines. The current system sets a homogeneous price for drugs from the same group. That is, it equals the value of creators qualitative He does not realize his additional innovation, and therefore, this change was expected.
“consent Amendment to additional innovation It was possible to be good news for patientsSources from many said Farmaindustria A Medical writingWith the addition that they will continue to work so that “The value of the additional innovation is identified How effective is for patients. “
In this sense, the employer defends that this type of innovation has some Favantry financing conditions It has the aim of not inhibiting their growth and offering therapeutic opportunities for the patients they need. Keep in mind that you provide multiple treatment options It brings flexibility when choosing treatment What suits the individual characteristics of each patient, as well as the ability to facilitate treatment management, and provides treatment opportunities for groups of Patients with non -advanced needs.
“This can have a positive effect on the quality of the patient’s life, among other things, which eventually means progress of the health system. Likewise, the gradual improvement within a therapeutic category often leads to a Reducing the cost associated with the disease, Both direct and indirect, derived from factors as less harmful effects, Improved or less efficient absenteeism The patient’s work, among other things, with the health savings of this, “details of the industry.
Reform the law of guarantees
What consists of reform submitted to the Security Law in the Public Health Agency Law? The idea was to include three exceptions to these people Reference price groups. The first refers to the medications that, “due to a new signal, a lower dose, a new pharmaceutical form, a drug feature or any other feature, produced objectively in a Improvement for patients or a strategic feature for SNS“In these cases, or exempt from the reference pricing system, it is evaluated with a factor that raises its reference price, but somehow you should belong to.
Moreover, the amendment adds another section to the article so that it is Medicines Committee between Medicines“Based on the proposal of a qualified body for the Ministry of Health”, you can “review the price of medicines listed in reference groups” in case “Admitted strategic drugs By the Spanish Agency for Medicines and Health Products (AEMPS).
The information published in the medical writing contains data, data and data from official institutions and health professionals. However, given any questions related to your health, consult the opposite health specialist.
